文献速递帕金森病与运动障碍

帕金森病患者特定生物型与疾病进展的关联

Association of specific biotypes in patients with Parkinson disease and disease progression.
PubMed 文献 · Neurology · 2020-08-14

该纵向分析基于PPMI队列314例新诊断帕金森病患者,利用T1加权MRI的变形形态学测量提取与临床评分相关的神经解剖特征,通过层次聚类识别出两种生物型。生物型1(n=114)皮层下脑体积小于健康对照,基线运动损害、自主神经功能障碍及REM睡眠行为障碍更重,平均5年随访中多个临床领域和多巴胺功能神经影像下降更快。生物型2(n=200)皮层下脑体积大于健康对照,进展较慢。

要点

  • 新诊断帕金森病可基于神经解剖特征分为两种生物型。
  • 皮层下脑体积较小的生物型1基线症状更重且进展更快。
  • 生物型可在诊断时检测并预测纵向病程,有助于试验设计。

核心结论

  • 帕金森病存在稳健的神经解剖生物型,具有不同的临床和神经解剖模式,可在诊断时检测并预测纵向进展。

研究设计与样本

  • 纵向分析,数据驱动聚类帕金森病患者来自帕金森病进展标志物计划(PPMI),样本量n=314,年龄61.0±9.5岁,女性34.1%,随访5年。
  • 采用T1加权MRI的变形形态学(DBM)估计体素级神经解剖特征,选取基线时与临床评分显著相关(p<0.01)的变形值体素进行层次聚类分析。

主要发现

  • 识别出两种神经解剖生物型:生物型1(n=114)皮层下脑体积小于健康对照,生物型2(n=200)皮层下脑体积大于健康对照。
  • 生物型1基线时运动损害、自主神经功能障碍及REM睡眠行为障碍均比生物型2更严重。
  • 尽管两生物型初诊和随访时病程相似,生物型1患者预后更差,平均5年内多个临床领域和-dopamine功能神经影像下降更迅速。

临床怎么用

  • 基于T1加权MRI的神经解剖生物型可在诊断时识别,用于预测帕金森病患者的纵向进展速度。
  • 生物型分型可能有助于临床试验设计和评估,针对进展更快的生物型1患者进行富集或分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify biotypes in patients with newly diagnosed Parkinson disease (PD) and to test whether these biotypes could explain interindividual differences in longitudinal progression. METHODS: In this longitudinal analysis, we use a data-driven approach clustering PD patients from the Parkinson's Progression Markers Initiative (n = 314, age 61.0 ± 9.5, years 34.1% female, 5 years of follow-up). Voxel-level neuroanatomic features were estimated with deformation-based morphometry (DBM) of T1-weighted MRI. Voxels with deformation values that were significantly correlated (p < 0.01) with clinical scores (Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale Parts I-III and total score, tremor score, and postural instability and gait difficulty score) at baseline were selected. Then, these neuroanatomic features were subjected to hierarchical cluster analysis. Changes in the longitudinal progression and neuroanatomic pattern were compared between different biotypes. RESULTS: Two neuroanatomic biotypes were identified: biotype 1 (n = 114) with subcortical brain volumes smaller than heathy controls and biotype 2 (n = 200) with subcortical brain volumes larger than heathy controls. Biotype 1 had more severe motor impairment, autonomic dysfunction, and much worse REM sleep behavior disorder than biotype 2 at baseline. Although disease durations at the initial visit and follow-up were similar between biotypes, patients with PD with smaller subcortical brain volume had poorer prognosis, with more rapid decline in several clinical domains and in dopamine functional neuroimaging over an average of 5 years. CONCLUSION: Robust neuroanatomic biotypes exist in PD with distinct clinical and neuroanatomic patterns. These biotypes can be detected at diagnosis and predict the course of longitudinal progression, which should benefit trial design and evaluation.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Wang L, Cheng W, Rolls ET, et al. Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology. 2020. PMID: 32817178. doi:10.1212/WNL.0000000000010498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。